ClinicalTrials.gg

TargetBeta

KIT

KIT proto-oncogene, receptor tyrosine kinase · also CD117, SCFR, C-Kit, PBT · CD molecules

15 programs in company-led studies act on KIT, from 13 companies: 8 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (12 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
regorafenibruleBayerphase 4404 runningABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEKChEMBL
imatinibruleNovartisphase 4703 runningABL1, BCR, PDGFRBChEMBL
AvapritinibruleSanofiphase 4102 runningPDGFRANCIt
velzatinibGlaxoSmithKlinephase 388 running–the company's pipeline
anlotinibruleSino Biopharmaceuticalphase 3407 runningFLT4, KDR, PDGFRBChEMBL
quizartinibruleDaiichi Sankyophase 3225 runningCSF1R, FLT3, PDGFRA, PDGFRB, RETChEMBL
masitinibruleAB Sciencephase 3384 runningFGFR3, PDGFRA, PDGFRBChEMBL
ripretinibruleOno Pharmaceuticalphase 393 runningPDGFRANCIt
seralutinibruleGB002, Inc., a wholly owned subsidiary of Gossamer Biophase 382 runningCSF1R, PDGFRA, PDGFRBChEMBL
elenestinibSanofiphase 331 running–the company's pipeline
NB-003ruleNingbo Newbay Technology Developmentphase 321 running–NCIt
BLU-808Sanofiphase 231 running–the company's pipeline
THB335ruleCalixisphase 221 running–the studies' text
briquilimabruleJasper Therapeuticsphase 270 running–NCIt
Anti-c-Kit/MMAE Antibody-Drug Conjugate NN3201ruleNovelty Nobilityphase 111 running–NCIt

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.